HU9200107D0 - Process for preventing or treating autoimmun uveoretinitis in mammals - Google Patents

Process for preventing or treating autoimmun uveoretinitis in mammals

Info

Publication number
HU9200107D0
HU9200107D0 HU92107A HU10792A HU9200107D0 HU 9200107 D0 HU9200107 D0 HU 9200107D0 HU 92107 A HU92107 A HU 92107A HU 10792 A HU10792 A HU 10792A HU 9200107 D0 HU9200107 D0 HU 9200107D0
Authority
HU
Hungary
Prior art keywords
uveoretinitis
treating
preventing
mammals
autoimmun
Prior art date
Application number
HU92107A
Other languages
English (en)
Other versions
HUT63182A (en
Inventor
Howard L Weiner
David A Hafler
Robert B Nussenblatt
Alan G Palestine
Original Assignee
Autoimmune Inc
Brigham & Womens Hospital
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc, Brigham & Womens Hospital, Nat Inst Health filed Critical Autoimmune Inc
Publication of HU9200107D0 publication Critical patent/HU9200107D0/hu
Publication of HUT63182A publication Critical patent/HUT63182A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Emergency Protection Circuit Devices (AREA)
HU92107A 1989-07-14 1990-07-16 Process for treating or preventing autoimmune uveoretinitis in mammals HUT63182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37977889A 1989-07-14 1989-07-14
US55163290A 1990-07-10 1990-07-10

Publications (2)

Publication Number Publication Date
HU9200107D0 true HU9200107D0 (en) 1992-04-28
HUT63182A HUT63182A (en) 1993-07-28

Family

ID=27008768

Family Applications (1)

Application Number Title Priority Date Filing Date
HU92107A HUT63182A (en) 1989-07-14 1990-07-16 Process for treating or preventing autoimmune uveoretinitis in mammals

Country Status (15)

Country Link
US (1) US5961977A (hu)
EP (1) EP0482089B1 (hu)
JP (1) JP2607751B2 (hu)
KR (1) KR0159046B1 (hu)
AT (1) ATE158950T1 (hu)
AU (1) AU670024B2 (hu)
BR (1) BR9007527A (hu)
CA (1) CA2063416C (hu)
DE (1) DE69031563T2 (hu)
DK (1) DK0482089T3 (hu)
ES (1) ES2109234T3 (hu)
FI (1) FI920139A0 (hu)
HU (1) HUT63182A (hu)
NO (1) NO920127D0 (hu)
WO (1) WO1991001333A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ATE367823T1 (de) 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
IL164202A0 (en) * 2002-03-26 2005-12-18 Yeda Res & Dev Use of an organ-specific pathogenic self-antigen for treatment of a non-autoimmune disease of said organ
EP1551495A4 (en) 2002-10-10 2010-06-02 Yeda Res & Dev BASIC ESTERS OF FAT ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMATORY AGENTS
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
JP6671363B2 (ja) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Ｃｄ４４の単離されたポリペプチドおよびその使用
EP3557958B1 (en) 2016-12-19 2023-07-12 Panasonic Intellectual Property Management Co., Ltd. Attachment device, electronic device, attachment device securing method, and sheet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336954C (en) * 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
DE69033487T2 (de) * 1989-12-20 2000-06-29 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol

Also Published As

Publication number Publication date
BR9007527A (pt) 1992-06-23
CA2063416C (en) 2000-05-30
US5961977A (en) 1999-10-05
HUT63182A (en) 1993-07-28
JPH05501866A (ja) 1993-04-08
KR0159046B1 (ko) 1998-11-16
FI920139A0 (fi) 1992-01-13
DE69031563D1 (de) 1997-11-13
EP0482089B1 (en) 1997-10-08
ES2109234T3 (es) 1998-01-16
DE69031563T2 (de) 1998-02-12
WO1991001333A1 (en) 1991-02-07
NO920127L (no) 1992-01-09
AU670024B2 (en) 1996-07-04
EP0482089A4 (en) 1993-02-17
CA2063416A1 (en) 1991-01-15
ATE158950T1 (de) 1997-10-15
AU6058390A (en) 1991-02-22
JP2607751B2 (ja) 1997-05-07
EP0482089A1 (en) 1992-04-29
DK0482089T3 (da) 1998-05-25
NO920127D0 (no) 1992-01-09

Similar Documents

Publication Publication Date Title
HU9200107D0 (en) Process for preventing or treating autoimmun uveoretinitis in mammals
GAUSEWITZ et al. The significance of early motion in the treatment of tibial plateau fractures.
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
IL99754A0 (en) Pharmaceutical composition for treatment of autoimmune diseases containing an autoantigen or a fragment or analogue thereof
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
EG19304A (en) Method of treating pre-menstrual syndrome
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
ATE258065T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
Gruner et al. Stimulation of the recruitment of epidermal Langerhans cells by splenopentin
JPS6461420A (en) Alpha-ethiocholanedione drug, and method of causing high hematic concentration alpha-ethiocholanone
EP0321094A3 (en) Treatment of factor viii inhibitors
Veys et al. Review of immunotherapy in rheumatoid arthritis
ZA895710B (en) The use of imexon as immune suppressive and pharmaceutical compositions containing imexon

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: THE GOVERNMENT OF THE UNITED STATES REPRESENTED B

Owner name: AUTOIMMUNE INC., US

DFC4 Cancellation of temporary protection due to refusal